Literature DB >> 24327315

Reversing multidrug-resistant by RNA interference through silencing MDR1 gene in human hepatocellular carcinoma cells subline Bel-7402/ADM.

Long Sheng1, Maoming Xiong, Cong Li, Xiangling Meng.   

Abstract

Multidrug resistance (MDR) in hepatocellular carcinoma (HC) significantly impedes the effect of chemotherapy and is considered as a primary reason leading to its recurrences and metastasis. The aim of present study was to explore new molecular targets for the reversal of MDR in HC by screening the adriamycin (ADM)-induced, human MDR-resistant HC cell subline Bel-7402/ADM. Small interfering RNAs (siRNAs) of four (MDR1si326, MDR1si1513, MDR1si2631 and MDR1si3071) targeting MDR1 were designed and transfected into Bel-7402/ADM cell strains. The experiments involved the following: mRNA expression of MDR1 gene by RT-PCR, P-glycoprotein (P-gp) expression by Western blot, intracellular ADM accumulation flow cytometry, and IC50 of ADM by a cytotoxic MTT assay. Four siRNAs reversed MDR in HC mediated by MDR1 to varying degrees. The expression level of MDR1 mRNA in cells of MDR1si326 or MDR1si2631 group (0.190 ± 0.038 or 0.171 ± 0.011) was more decreased. The expression level of P-gp in cells of MDR1si326 group was the lowest. The accumulation of ADM in cells of MDR1si326 or MDR1si2631 group (77.0 ± 3.5 or 75.4 ± 2.9) was more increased. The IC50 of cells to ADM was lowest in MDR1si326 group (11.32 ± 0.69 mg/L). Compared with other three siRNAs, MDR1si326 performed the optimal reversal effect of drug resistance in human HC Bel-7402/ADM.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24327315     DOI: 10.1007/s12253-013-9726-x

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  41 in total

Review 1.  Post-transcriptional gene silencing by siRNAs and miRNAs.

Authors:  Witold Filipowicz; Lukasz Jaskiewicz; Fabrice A Kolb; Ramesh S Pillai
Journal:  Curr Opin Struct Biol       Date:  2005-06       Impact factor: 6.809

Review 2.  A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein (ABCB1).

Authors:  Suresh V Ambudkar; Zuben E Sauna; Michael M Gottesman; Gergely Szakacs
Journal:  Trends Pharmacol Sci       Date:  2005-08       Impact factor: 14.819

Review 3.  Molecular and functional characterization of P-glycoprotein in vitro.

Authors:  Gary N Y Chan; Reina Bendayan
Journal:  Methods Mol Biol       Date:  2011

4.  Stat3 as a molecular target in RNA interference-based treatment of oral squamous cell carcinoma.

Authors:  Sebastian Krystian Klosek; Koh-ichi Nakashiro; Shingo Hara; Hiroyuki Goda; Hiroyuki Hamakawa
Journal:  Oncol Rep       Date:  2008-10       Impact factor: 3.906

5.  Role of siRNA silencing of MMP-2 gene on invasion and growth of laryngeal squamous cell carcinoma.

Authors:  Yanan Sun; Ming Liu; Baofeng Yang; Baoxin Li; Jianguang Lu
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-04-25       Impact factor: 2.503

6.  Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients.

Authors:  P A Speth; P C Linssen; J B Boezeman; H M Wessels; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Reversion of multidrug resistance in human glioma by RNA interference.

Authors:  Peng Zhao; Yazhuo Zhang; Meizhen Sun; Yue He
Journal:  Neurol Res       Date:  2008-07       Impact factor: 2.448

8.  Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi).

Authors:  Christiane Nieth; Axel Priebsch; Alexandra Stege; Hermann Lage
Journal:  FEBS Lett       Date:  2003-06-19       Impact factor: 4.124

9.  Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods.

Authors:  Xingguo Zhong; Maoming Xiong; Xiangling Meng; Renhua Gong
Journal:  J Exp Clin Cancer Res       Date:  2010-08-20

10.  miRNA-target prediction based on transcriptional regulation.

Authors:  Toyofumi Fujiwara; Tetsushi Yada
Journal:  BMC Genomics       Date:  2013-02-15       Impact factor: 3.969

View more
  1 in total

1.  MicroRNA-34a-5p enhances sensitivity to chemotherapy by targeting AXL in hepatocellular carcinoma MHCC-97L cells.

Authors:  Xiao-Yun Li; Jing-Yun Wen; Chang-Chang Jia; Tian-Tian Wang; Xing Li; Min Dong; Q U Lin; Zhan-Hong Chen; Xiao-Kun Ma; L I Wei; Ze-Xiao Lin; Dan-Yun Ruan; Jie Chen; Dong-Hao Wu; Wei Liu; Yan Tai; Zhi-Yong Xiong; Xiang-Yuan Wu; Q I Zhang
Journal:  Oncol Lett       Date:  2015-08-28       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.